Cost of depression: effect of adherence and treatment response
Abstract
OBJECTIVES: The purpose of the present study has been to assess the societal cost of major depression and the distribution into different cost components. The impact of adherence and treatment response was also explored. METHOD: Data were collected from a randomized controlled trial of patients with major depressive disorder who were treated in a naturalistic primary care setting. Resource use and quality of life were followed during the two-year trial. RESULTS: The mean total cost per patient during two years was KSEK 363 (EUR 38 953). Indirect costs were the most important component (87%), whereas the cost of drugs was minor (4.5%). No significant differences in costs or quality of life between treatment arms or between adherent and non-adherent patients were demonstrated. However, treatment responders had 39% lower total costs per patient and experienced a larger increase in quality of life compared to non-responders. CONCLUSIONS: Major depression has high costs for society, primarily due to indirect costs. Treatment responders have considerably lower costs per patient and higher quality of life than non-responders. This indicates that measures to increase response rates are also important from an economic perspective.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The per person average cost of productivity loss for a single day of work absence in Sweden is estimated to be US$190.
“The per person average cost of productivity loss for a single day of work absence in Sweden is estimated to be US$190 [39].”
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736 · see citing works
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Generalized Estimating Equations
Hardin, J. W., & Hilbe, J. M. (2002) · doi:10.1201/9781420035285 · Cited by 1,766 · see citing works
Global burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735 · see citing works
Greenberg, P. E., Stiglin, L. E., Finkelstein, S. N., & Berndt, E. R. (1994) · PharmacoResources · doi:10.1007/bf03289581 · Cited by 974 · see citing works
Swedish population health-related quality of life results using the EQ-5D
Burström, K., Johannesson, M., & Diderichsen, F. (2001) · Quality of Life Research · doi:10.1023/a:1013171831202 · Cited by 664 · see citing works
Treatment non‐adherence in affective disorders
Lingam, R., & Scott, J. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.1r084.x · Cited by 635 · see citing works
Social Functioning in Depression: A Review
Hirschfeld, R. M. A., Montgomery, S. A., Keller, M. B., Kasper, S., Schatzberg, A. F., Moller, H.-J., Healy, D., Baldwin, D., Humble, M., Versiani, M., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0405 · Cited by 586 · see citing works
Lépine, J., Gastpar, M., Mendlewicz, J., & Tylee, A. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199701000-00003 · Cited by 482 · see citing works
The economic burden of depression
Stoudemire, A., Frank, R. W., Hedemark, N., Kamlet, M. S., & Blazer, D. G. (1986) · General Hospital Psychiatry · doi:10.1016/0163-8343(86)90018-6 · Cited by 480 · see citing works
Patient adherence in the treatment of depression
Pampallona, S., Bollini, P., Tibaldi, G., Kupelnick, B., & Munizza, C. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.2.104 · Cited by 291 · see citing works
The underrecognition and undertreatment of depression: what is the breadth and depth of the problem?
Davidson, J. R. T., & Meltzer-Brody, S. E. (1999) · PubMed · Cited by 282 · see citing works
Recovery from depression, work productivity, and health care costs among primary care patients
Simon, G. E., Revicki, D. A., Heiligenstein, J. H., Grothaus, L. C., VonKorff, M., Katon, W. J., & Hylan, T. R. (2000) · General Hospital Psychiatry · doi:10.1016/s0163-8343(00)00072-4 · Cited by 267 · see citing works
The Valuation of Human Capital
Weisbrod, B. A. (1961) · Journal of Political Economy · doi:10.1086/258535 · Cited by 236 · see citing works
Workplace performance effects from chronic depression and its treatment
Berndt, E. R., Finkelstein, S. N., Greenberg, P. E., Howland, R. H., Keith, A., Rush, A. J., Russell, J. D., & Keller, M. B. (1998) · Journal of Health Economics · doi:10.1016/s0167-6296(97)00043-x · Cited by 213 · see citing works
The incidence of first-onset depression in a population followed from the age of 70 to 85
Palsson, S. P., Östling, S., & Skoog, I. G. (2001) · Psychological Medicine · doi:10.1017/s0033291701004524 · Cited by 147 · see citing works
Lydiard, R. B., Stahl, S. M., Hertzman, M., & Harrison, W. M. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1104 · Cited by 126 · see citing works
A Prospective Study of First-Incidence Depression
Rorsman, B., Gräsbeck, A., Hagnell, O., Lanke, J., Öhman, R., Öjesjö, L., & Otterbeck, L. (1990) · The British Journal of Psychiatry · doi:10.1192/bjp.156.3.336 · Cited by 112 · see citing works
Adolescent depression: prevalence in Swedish high‐school students
Olsson, G. I., & von Knorring, A. ‐. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb07237.x · Cited by 107 · see citing works
Absenteeism Among Employees Treated for Depression
Claxton, A. J., Chawla, A., & Kennedy, S. (1999) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-199907000-00009 · Cited by 84 · see citing works
And now for vertical equity? Some concerns arising from Aboriginal health in Australia
MOONEY, G. H. (1996) · Health Economics · doi:10.1002/(sici)1099-1050(199603)5:2 · Cited by 76 · see citing works
Cost of illness studies in health care: a comparison of two cases
Ament, A. J. H. A., & Evers, S. (1993) · Health Policy · doi:10.1016/0168-8510(93)90076-2 · Cited by 68 · see citing works
kerblad, A.-C., Bengtsson, F., Ekselius, L., & von Knorring, L. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200311000-00006 · Cited by 66 · see citing works
Self-citationThe impact of depression is unevenly distributed in the population
Isacson, D. G. L., Bingefors, K., & von Knorring, L. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.12.011 · Cited by 44 · see citing works
Self-citationÅkerblad, A., Bengtsson, F., Ekselius, L., et al. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000091305.72168.6e · Cited by 28 · see citing works
Self-citationKutcher, S., LeBlanc, J. C., MacLaren, C., & Hadrava, V. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00313-x · Cited by 27 · see citing works
Turner, R. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199406003-00005 · Cited by 24 · see citing works
Group living for elderly patients with dementia — A cost analysis
Svensson, M., Edebalk, P. G., & Persson, U. (1996) · Health Policy · doi:10.1016/0168-8510(96)00839-1 · Cited by 17 · see citing works
Nortriptyline toxicity secondary to interaction with bupropion sustained-release
Weintraub, D. A. (2001) · Depression and Anxiety · doi:10.1002/1520-6394(2001)13:1 · Cited by 16 · see citing works
Norinder, A., Nordling, S., & Häggström, L. (2000) · PubMed · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H. ‐., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K. M., Gerlach, M., Greiner, C., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,466 · see citing works
“Moreover, TDM has the potential to enhance cost-effectiveness of neuropsychopharmacotherapy [13, 894, 961, 1204, 1267].”
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321 · see citing works
Sariaslan, A., Sharp, D. J., D’Onofrio, B. M., Larsson, H., & Fazel, S. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002103 · Cited by 262 · see citing works
“The per person average cost of productivity loss for a single day of work absence in Sweden is estimated to be US$190 [39].”
BackgroundTranscranial direct current stimulation in severe, drug-resistant major depression
Ferrucci, R., Bortolomasi, M., Vergari, M., Tadini, L., Salvoro, B., Giacopuzzi, M., Barbieri, S., & Priori, A. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.015 · Cited by 228 · see citing works
Lundberg, J., Cars, T., Lööv, S., Söderling, J. K., Sundström, J., Tiihonen, J., Levál, A., Gannedahl, A., Björkholm, C., Själin, M., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3860 · Cited by 168 · see citing works
“7% women; median [IQR] age, 42 years [30-56]).”
Lappalainen, P., Langrial, S., Oinas-Kukkonen, H., Tolvanen, A., & Lappalainen, R. (2015) · Behavior Modification · doi:10.1177/0145445515598142 · Cited by 115 · see citing works
The societal cost of depression: Evidence from 10,000 Swedish patients in psychiatric care
Ekman, M., Granström, O., Omérov, S., Jacob, J., & Landén, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.03.003 · Cited by 101 · see citing works
“The total costs in our study were higher than in the Swedish studies by Norinder et al. (2000) and Sobocki et al. (2007b; 2007c), but lower than in the study by von Knorring et al. (2006).”
BackgroundMethodResultInfluentialDell’Osso, B. M., Zanoni, S., Ferrucci, R., Vergari, M., Castellano, F., D’Urso, N., Dobrea, C., Benatti, B., Arici, C., Priori, A., et al. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.008 · Cited by 89 · see citing works
Working‐memory fMRI reveals cingulate hyperactivation in euthymic major depression
Schöning, S., Zwitserlood, P., Engelien, A., Behnken, A., Kugel, H., Schiffbauer, H., Lipina, K., Pachur, C., Kersting, A., Dannlowski, U., et al. (2009) · Human Brain Mapping · doi:10.1002/hbm.20702 · Cited by 81 · see citing works
“…disorders leading to a dramatic reduction of quality of life, increased mortality risk, (Alonso and Lepine, 2007; Cuijpers and Smit, 2002) and causing a significant individual and economic burden as the most costly brain disorder in Europe (Sobocki et al., 2006; von Knorring et al., 2006).”
BackgroundPedersen, I., Nordaunet, T., Martinsen, E. W., Berget, B., & Braastad, B. O. (2011) · Issues in Mental Health Nursing · doi:10.3109/01612840.2011.566982 · Cited by 75 · see citing works
Uppsala Longitudinal Adolescent Depression Study (ULADS)
Alaie, I., Philipson, A., Ssegonja, R., Hagberg, L., Feldman, I., Sampaio, F., Möller, M., Arinell, H., Ramklint, M., Päären, A., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024939 · Cited by 63 · see citing works
Self-citationRamsberg, J., Asseburg, C., & Henriksson, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042003 · Cited by 57 · see citing works
“These data were corroborated by another Swedish primary care study which had used response rather than remission as endpoint [22].”
ResultFarm Animal-Assisted Intervention for People with Clinical Depression: A Randomized Controlled Trial
Pedersen, I., Martinsen, E. W., Berget, B., & Braastad, B. O. (2012) · Anthrozoös · doi:10.2752/175303712x13316289505260 · Cited by 56 · see citing works
“However, non-responders and lack of adherence is problematic in antidepressant treatment (Fava 2003; von Knorring et al. 2006), and psychotherapy is only available for a minority of those in need of it.”
BackgroundBeyond Symptomatic Improvement
Langlieb, A. M., & Guico‐Pabia, C. J. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09r00826blu · Cited by 51 · see citing works
Mandelli, L., Nearchou, F., Vaiopoulos, C., Stefanis, C. N., Vitoratou, S., Serretti, A., & Stefanis, N. C. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.001 · Cited by 49 · see citing works
Eap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M., de León, J., Greiner, C., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1878427 · Cited by 49 · see citing works
Oberjé, E. J. M., de Kinderen, R. J. A., Evers, S., van Woerkum, C. M. J., & de Bruin, M. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0108-8 · Cited by 44 · see citing works
“Four studies evaluated adherence-improving interventions for patients with mental illness [25, 29, 35, 36].”
Stein-Shvachman, I. (2013) · Aging and Disease · doi:10.14336/ad.2013.0400329 · Cited by 42 · see citing works
“At the social level, treatment nonadherence is associated with increased costs, mostly due to indirect expenses – such as a loss of productivity resulting from absenteeism and early retirement [50].”
BackgroundFox, J. K., Halpern, L. F., & Forsyth, J. P. (2008) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2008.00129.x · Cited by 41 · see citing works
Antidepressant Treatment and Altered CYP2D6 Activity
D’Empaire, I., Guico‐Pabia, C. J., & Preskorn, S. (2011) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000405363.95881.01 · Cited by 41 · see citing works
Resource use and costs associated with patients treated for depression in primary care
Sobocki, P., Ekman, M., Ågren, H., Krakau, I., Runeson, B., Mårtensson, B., & Jönsson, B. (2006) · The European Journal of Health Economics · doi:10.1007/s10198-006-0008-3 · Cited by 40 · see citing works
“[12] found an even higher indirect cost per patient at € 34,000 over two years, representing 87% of the”
BackgroundResultDuevel, J. A., Hasemann, L., Peña-Longobardo, L. M., Rodríguez-Sánchez, B., Aranda-Reneo, I., Oliva-Moreno, J., López-Bastida, J., & Greiner, W. (2020) · Health Economics Review · doi:10.1186/s13561-020-00288-7 · Cited by 34 · see citing works
Funk, C. S. M., Hart, X. M., Gründer, G., Hiemke, C., Elsner, B., Kreutz, R. H., & Riemer, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.826138 · Cited by 32 · see citing works
Lundberg, J., Cars, T., Lööv, S., Söderling, J. K., Tiihonen, J., Levál, A., Gannedahl, A., Björkholm, C., Själin, M., & Hellner, C. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13414 · Cited by 24 · see citing works
Hamre, H. J., Witt, C. M., Glockmann, A., Ziegler, R., Kienle, G. S., Willich, S. N., & Kiene, H. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-009-0203-0 · Cited by 22 · see citing works
Adherence to Medication in Depressive Patients
Roca, M., Armengol, S., Salvador‐Carulla, L., Monzón, S., Salvá, J., & Gili, M. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182223af9 · Cited by 22 · see citing works
The Social Cost of Major Depression. A Systematic Review
Coretti, S., Rumi, F., & Cicchetti, A. (2019) · Review of European Studies · doi:10.5539/res.v11n1p73 · Cited by 22 · see citing works
“In Europe, on average, the impact of drugs on the overall cost of disease is 20,32%, with only two studies reporting a figure higher than 30% (von Knorring et al., 2006; Klein-Budde et al., 2013).”
BackgroundResultInfluentialUptake of Medicare Benefits Schedule items by psychologists and other mental health practitioners
Whiteford, H., Doessel, D. P., & Sheridan, J. S. (2008) · Clinical Psychologist · doi:10.1080/13284200802220109 · Cited by 21 · see citing works
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder
Arnaud, A. M., Suthoff, E. D., Tavares, R. M., Zhang, X., & Ravindranath, A. J. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01021-w · Cited by 20 · see citing works
“In addition, substantial indirect costs, including decreased productivity due to illness, sickness absence from work, and early retirement, have been reported among MDD patients [48, 51, 52].”
BackgroundLima, A. F. B. D. S., & Fleck, M. P. D. A. (2011) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462011000300007 · Cited by 20 · see citing works
“Beyond the medical perspective, there is also evidence that the therapy with antidepressants reduces the indirect costs of depression by decreasing the number of workdays lost and increasing productivity.(25) Therefore, the low rate of complete remission in our study, of around 25%, is probably mainly due to the diffi…”
BackgroundHart, X. M., Gründer, G., Unterecker, S., Schoretsanitis, G., Hiemke, C., Adamovic, I., Amann, F., Baumann, P., Bergemann, N., Brandt, C., et al. (2026) · Pharmacopsychiatry · doi:10.1055/a-2860-7861 · Cited by 20 · see citing works
García‐Pérez, L., Linertová, R., Serrano-Pérez, P., Trujillo‐Martín, M. M., Rodríguez‐Rodríguez, L., Valcárcel‐Nazco, C., & del Pino‐Sedeño, T. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1782434 · Cited by 18 · see citing works
Jensen, K. J., Gronemann, F. H., Ankarfeldt, M. Z., Jimenez-Solem, E., Alulis, S., Riise, J., Bødker, N., Osler, M., & Petersen, J. (2022) · PLOS ONE · doi:10.1371/journal.pone.0275299 · Cited by 15 · see citing works
“Two reviews of healthcare resource utilization (HRU) in depression from 2014 and 2019 [16, 17] found that TRD patients experience higher costs than non-TRD patients with the majority of studies being United States (US)-based, only one study was from Scandinavia [18].”
BackgroundThe Distribution of Mental Health Service Costs for Depression in the Alberta Population
Slomp, M., Jacobs, P., Ohinmaa, A. E., Bland, R. C., Block, R., Dewa, C. S., & Wang, C. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700907 · Cited by 14 · see citing works
Piccoli, E., Cerioli, M., Castiglioni, M., Larini, L., Scarpa, C., & Dell’Osso, B. M. (2022) · International Review of Psychiatry · doi:10.1080/09540261.2022.2132137 · Cited by 13 · see citing works
“Depression, either bipolar or unipolar, is a highly prevalent condition (Greenberg et al., 2015; Kupka et al., 2007; von Knorring et al., 2006): according to the World Health Organisation (WHO) it is the leading cause of disability worldwide (Smith, 2014) and it will represent the highest sanitary…”
BackgroundSertraline – isolation methods and quantitation in biological material
Dziurkowska, E., & Wesołowski, M. (2018) · Psychiatria Polska · doi:10.12740/pp/85788 · Cited by 13 · see citing works
“This also helped to improve patient quality of life [23].”
BackgroundIssues in Adherence to Treatment With Monoamine Oxidase Inhibitors and the Rate of Treatment Failure
Cohen, L. J., & Sclar, D. A. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11096su1c.05 · Cited by 8 · see citing works
Nadai, A. S. D., Karver, M. S., Murphy, T. K., Cavitt, M. A., Alvaro, J. L., Bengtson, M. A., Stock, S. L., Rakhshani, A. C., & Storch, E. A. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0263 · Cited by 8 · see citing works
“While data on the adherence-outcome relationship are limited in pediatric psychopharmacology, nonadherence to sertraline has been associated with a nearly 30% reduction in response rates in adult depression (von Knorring et al. 2006).”
BackgroundJeżuchowska, A., Cybulska, A. M., Rachubińska, K., Skonieczna‐Żydecka, K., Reginia, A., Pańczyk, M., Ćwiek, D., Grochans, E., & Schneider-Matyka, D. (2024) · Healthcare · doi:10.3390/healthcare12232484 · Cited by 7 · see citing works
Major Depresif Bozuklukta Tedavi Hedefleri ve Tedavinin İzlenmesi
Aydemır, Ö. (2011) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2011.11790743 · Cited by 6 · see citing works
“İsveç’te yürütülen bir doğal izleme çalışmasında ise iki yıl boyunca izlenen bir majör depresif bozukluk hastasının toplam ortalama maliyeti 38,953 Avro olarak hesaplanmıştır (34).”
Sundberg, T., & Falkenberg, T. (2014) · Complementary Medicine Research · doi:10.1159/000363635 · Cited by 5 · see citing works
Kan, K., Feenstra, T., de Vries, S. O., Visser, E., Schoevers, R. A., & Jörg, F. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.010 · Cited by 5 · see citing works
Akram, A., Al‐Sabahy, M., Al-Jedai, A. H., Almudaiheem, H., Farghally, M., Fallata, E. O., Alibrahim, O. A., Shoukry, T. M., Basu, S., Chalouhi, D., et al. (2022) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1952 · Cited by 4 · see citing works
Venkata, P. K. T., Bolla, D., Donthu, R., Pathak, A., & Gudimetla, A. (2024) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00420-x · Cited by 4 · see citing works
“%) were observed in a randomized control trial (RCT) [22] with antidepressant treatment over 6 months.”
BackgroundChen, B., McDermott, S. W., Salzberg, D., Zhang, W., & Hardin, J. W. (2024) · Medical Care · doi:10.1097/mlr.0000000000001946 · Cited by 4 · see citing works
The economic burden of treatment-resistant depression: Cost-of-illness perspective
Niazi, S. K., & Bobo, W. V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00003-7 · Cited by 2 · see citing works
Compliance among patients with depressive and anxiety disorders
Gorostowicz, A., Wasik, A., Krupa, A. J., Oddział Kliniczny Psychiatrii Dorosłych, D. I. M., & Siwek, M. (2019) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2019.0018 · Cited by 2 · see citing works
PMH17 RESOURCE-USE AND COSTS ASSOCIATED WITH PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE
Sobocki, P., Ekman, M., Agren, H., Krakau, I., Runeson, B., Mårtensson, B., & Jönsson, B. (2006) · Value in Health · doi:10.1016/s1098-3015(10)64518-4 · Cited by 1 · see citing works
“[12] found an even higher indirect cost per patient at € 34,000 over two years, representing 87% of the”
BackgroundResultInfluential5-HT2A a serotonin receptor with a possible role in joint diseases
Kling, A. (2013) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1 · see citing works
Biersack, K., Sattel, H. C., Schönweger, P., Kaspar, L., Lehnen, N., Gensichen, J. S., Henningsen, P., & the POKAL group (2023) · medRxiv · doi:10.1101/2023.12.27.23297265 · Cited by 1 · see citing works
Mood disorders and consequences of pharmacological treatment
Viktorin, A. (2015) · Figshare
Onderzoek naar de begeleiding van patiënten met depressie in de openbare apotheek
Liekens, S., & Foulon, V. (2010) · Lirias
Pasterkiewicz, U. B. (2017) · UWSpace (University of Waterloo)
Jeżuchowska, A., Cybulska, A. M., Rachubińska, K., Reginia, A., Pańczyk, M., Ćwiek, D., Grochans, E., & Schneider-Matyka, D. (2024) · Research Square · doi:10.21203/rs.3.rs-4648228/v1
Biersack, K., Sattel, H. C., Schönweger, P., Kaspar, L., Lehnen, N., Gensichen, J. S., Henningsen, P., & for the POKAL group (2025) · PLoS ONE · doi:10.1371/journal.pone.0293713
Thatisetti Venkata, P. K., Bolla, D., Donthu, R. K., Pathak, A., & Gudimetla, A. (2024) · Figshare · doi:10.6084/m9.figshare.26694966
A Review of Methods Used to Assess Treatment Tolerability in Clinical Trials
Gnanasakthy, A., Mordin, M., Chang, J., Mazar, I., Rosa, A. I. D., Banjara, B., Lusk, J., & Harrington, M. (2026) · Patient · doi:10.1007/s40271-026-00834-1
- Authors
- von Knorring, L., Åkerblad, A.-C., Bengtsson, F., Carlsson, Å., & Ekselius, L.
- Affiliations
- Uppsala University (SE)
- Linköping University (SE)
- ORCID
- Ekselius, L.
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2006-09
- Volume
- 21
- Issue
- 6
- Pages
- 349-354
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W2001501232
- Cited by
- 58
- References
- 32
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 1 · 2022: 7 · 2021: 2 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 4 · 2012: 4
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- major depressive disorder, medication adherence, treatment response, indirect costs, quality of life, resource utilization (health care), primary care, antidepressant treatment
- MeSH terms
- Antidepressive Agents, Demography, Major Depressive Disorder, Female, Follow-Up Studies, Humans, Male, Mental Health Services, Middle Aged, Patient Compliance, Primary Health Care, Quality of Life, Surveys and Questionnaires, Social Environment, Drug Monitoring, Health Care Costs, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
